Amicus (FOLD) Gets Japan Approval for Pombiliti + Opfolda

Amicus Therapeutics, Inc. (NASDAQ:FOLD) is one of the 10 Best Small-Cap Stocks to Buy According to Billionaires. On June 25, Amicus Therapeutics, Inc. (NASDAQ:FOLD) reported that it received approval for Pombiliti (cipaglucosidase alfa) + Opfolda (miglustat) for the treatment of adults with late-onset Pompe disease (LOPD) from Japan’s Ministry of Health, Labour and Welfare (MHLW).

According to the report by Amicus Therapeutics, Inc. (NASDAQ:FOLD), Pombiliti + Opfolda works as a two-component therapy. Pombiliti is a special enzyme designed for increased uptake into muscle cells, while Opfolda is an enzyme stabilizer that helps keep this enzyme stable in the blood.

Amicus Therapeutics, Inc. (NASDAQ:FOLD) has now received approvals for Pombiliti + Opfolda in the United States, the European Union, the United Kingdom, Canada, Australia, Switzerland, and Japan.

Amicus Therapeutics, Inc. (NASDAQ:FOLD) is an American biopharmaceutical company that discovers, develops, and delivers novel medicines for people living with rare diseases.

While we acknowledge the potential of FOLD as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 10 Best American Semiconductor Stocks to Buy Now and 11 Best Fintech Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.